成人B-ALL患者在CD19 CAR-T治疗后进展的干预与结局
该研究回顾性分析38例CD19 CAR-T治疗后进展的成人B-ALL患者,中位进展时间5.5个月,进展后中位生存7.5个月。79%接受挽救治疗,43%达完全缓解但缓解短暂;blinatumomab和/或inotuzumab使58.3%患者达CR。多因素分析显示CAR-T缓解持续时间长与进展后生存优相关。
要点
- CAR-T输注时高疾病负荷与进展风险显著相关。
- 进展后挽救治疗CR率43%,但缓解持续时间短。
- blinatumomab和/或inotuzumab可使58.3%患者达CR。
核心结论
- 成人B-ALL患者CD19 CAR-T治疗后进展总体预后差,但部分患者对挽救治疗(包括blinatumomab、inotuzumab和CAR-T再输注)可获得持续缓解。
研究设计与样本
- 单中心回顾性研究,纳入38例CD19 CAR-T治疗后进展的成人B-ALL患者。
主要发现
- CAR-T治疗后中位进展时间5.5个月,进展后中位生存7.5个月。
- CAR-T输注时高疾病负荷与进展风险显著相关。
- 12例接受blinatumomab和/或inotuzumab者中7例(58.3%)达CR。
- 多因素分析显示CAR-T缓解持续时间较长与进展后生存优相关。
临床怎么用
- 对CD19 CAR-T治疗后进展的成人B-ALL,可考虑blinatumomab和/或inotuzumab等挽救治疗。
- CAR-T输注时疾病负荷高者需关注进展风险。
局限性
- 单中心回顾性研究,样本量38例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become a breakthrough treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, despite the high initial response rate, the majority of adult patients with B-ALL progress after CD19 CAR T-cell therapy. Data on the natural history, management, and outcome of adult B-ALL progressing after CD19 CAR T cells have not been described in detail. Herein, we report comprehensive data of 38 adult patients with B-ALL who progressed after CD19 CAR T therapy at our institution. The median time to progression after CAR T-cell therapy was 5.5 months. Median survival after post-CAR T progression was 7.5 months. A high disease burden at the time of CAR T-cell infusion was significantly associated with risk of post-CAR T progression. Thirty patients (79%) received salvage treatment of post-CAR T disease progression, and 13 patients (43%) achieved complete remission (CR), but remission duration was short. Notably, 7 (58.3%) of 12 patients achieved CR after blinatumomab and/or inotuzumab administered following post-CAR T failure. Multivariate analysis revealed that a longer remission duration from CAR T cells was associated with superior survival after progression following CAR T-cell therapy. In summary, overall prognosis of adult B-ALL patients progressing after CD19 CAR T cells was poor, although a subset of patients achieved sustained remissions to salvage treatments, including blinatumomab, inotuzumab, and reinfusion of CAR T cells. Novel therapeutic strategies are needed to reduce risk of progression after CAR T-cell therapy and improve outcomes of these patients.
引用
- Wudhikarn K, Flynn JR, Rivière I, et al. Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy. Blood. 2021. PMID: 33851211. doi:10.1182/blood.2020009515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。